Company: PRGO
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001585364-25-000122
Chunk: 126

Company: PERRIGO Co plc
Filing Date: 2025-08-06
Form: 10-Q
Item: Part II, Item 1
Chunk 126
---
 absence of Plackers® dental flossers promotions compared to the prior year. 

•Skin Care: Net sales of $57.8 million increased 1.2% driven by growth in the Mederma® brand and higher net sales in the Minoxidil franchise.

•Women's Health: Net sales of $18.7 million increased 11.3% due primarily to growth of Opill®, as the prior year quarter reflected a relatively light sales period following the strong retail sell-in that occurred immediately after the product’s launch in March 2024..

•VMS and Other: Net sales of $3.1 million decreased 42.9% due primarily to volume decline in the VMS category.

44

Perrigo Company plc - Item 2CSCA

Operating income decreased $24.2 million, or 34.9%, due primarily to:

•$26.9 million decrease in gross profit primarily driven by isolated production variability in infant formula, which caused an increase in product scrap in the second quarter, and lower net sales volumes primarily in U.S. OTC. These factors were partially offset by favorable impacts from lower materials inflation and savings from Project Energize. Gross profit as a percentage of net sales decreased 370 basis points compared to the prior year due primarily to the same factors that drove gross profit.

•$2.7 million decrease in operating expenses due primarily to lower selling costs of $7.4 million due primarily to Project Energize, partially offset by bad debt expense recognized primarily related to a customer bankruptcy and higher restructuring costs compared to the prior year period.

Six Month Comparison

 Six Months Ended(in millions, except percentages)June 28, 2025June 29, 2024Net sales$1,242.8 $1,278.3 Gross profit$362.8 $343.3 Gross profit %29.2 %26.9 %Operating income$109.1 $85.0 Operating income %8.8 %6.6 %

Net sales decreased $35.5 million, or 2.8%, due primarily to:

•$35.0 million decrease, or 2.7%, due primarily to lower net sales in the Digestive Health category of $35.5 million, a prior year benefit in the Women's Health category of $18.0 million from initial retailer stocking of Opill® which launched at the end of